Overview

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

This Phase 1 dose-escalation trial is to determine the safety, tolerability and recommended phase 2 dose of talazoparib in combination with belinostat in subjects with Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer.

Phase:

Phase 1

Details

Lead Sponsor:

University of Michigan Rogel Cancer Center

Collaborators:

Acrotech Biopharma LLC
Pfizer

Treatments:

Belinostat
Talazoparib